Literature DB >> 10871757

T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition.

A Hombach1, C Heuser, M Gerken, B Fischer, K Lewalter, V Diehl, C Pohl, H Abken.   

Abstract

T cells can be endowed with antigen specificity by grafting with a chimeric receptor consisting of an extracellular antigen binding moiety (scFv) derived from an antibody and an intracellular signaling domain. Conflicting data exist on the impact of an extracellular spacer domain between the antigen binding and the signaling domain with respect to cellular activation. Here, we recorded conjugate formation and antigen-driven cellular activation of T cells grafted with receptor molecules that contain the same antigen binding site (anti-CD30 HRS3-scFv) and signaling domain (FcepsilonRI gamma-chain), however, with and without an IgG1 CH2CH3 (Fc) spacer domain between the scFv and transmembrane moiety. Receptors of both configurations mediate equally efficient conjugate formation between receptor grafted T cells and antigen-positive target cells. Specific signaling by the spacer containing receptor, however, is blocked by five- to 10-fold lower concentrations of soluble antigen than by the spacer-less receptor indicating a higher avidity of the spacer containing receptor to soluble antigen. In contrast, cellular activation upon binding to antigen-positive cells is mediated more efficiently by the spacer-less receptor. This demonstrates that the extracellular spacer domain impairs antigen-dependent cellular activation by the chimeric immune receptor, but not intercellular conjugate formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871757     DOI: 10.1038/sj.gt.3301195

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

1.  Fine-tuning the CAR spacer improves T-cell potency.

Authors:  Norihiro Watanabe; Pradip Bajgain; Sujita Sukumaran; Salma Ansari; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

Review 2.  Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Authors:  Marcela V Maus; Stephan A Grupp; David L Porter; Carl H June
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

3.  A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv.

Authors:  E Faitschuk; V Nagy; A A Hombach; H Abken
Journal:  Gene Ther       Date:  2016-06-14       Impact factor: 5.250

Review 4.  How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.

Authors:  Albert T Gacerez; Benjamine Arellano; Charles L Sentman
Journal:  J Cell Physiol       Date:  2016-06-02       Impact factor: 6.384

Review 5.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

6.  Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2019-06-19       Impact factor: 11.454

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Authors:  Gregory A Rufener; Oliver W Press; Philip Olsen; Sang Yun Lee; Michael C Jensen; Ajay K Gopal; Barbara Pender; Lihua E Budde; Jeffrey K Rossow; Damian J Green; David G Maloney; Stanley R Riddell; Brian G Till
Journal:  Cancer Immunol Res       Date:  2016-04-21       Impact factor: 11.151

9.  Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

Authors:  Andreas A Hombach; André Görgens; Markus Chmielewski; Florian Murke; Janine Kimpel; Bernd Giebel; Hinrich Abken
Journal:  Mol Ther       Date:  2016-04-26       Impact factor: 11.454

Review 10.  The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.

Authors:  Sarah J Nagle; Alfred L Garfall; Edward A Stadtmauer
Journal:  Cancer J       Date:  2016 Jan-Feb       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.